Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A luminescent attenuated SARS-CoV-2 for the identification and validation of drug-resistant mutants.

Journal of virology - 23 Sept 2025

Ma Yao, Ye Chengjin, Khalil Ahmed Magdy, Mahmoud Sara H, Sobolik Elizabeth B, Greninger Alexander L, Castro Esteban, Jackson Nathaniel, Bayoumi Mahmoud, Plemper Richard K, Martinez-Sobrido Luis

Abstract excerpt

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has necessitated a continuous updating of vaccines. In contrast, antivirals remained effective as they target conserved viral proteins that are essential for the viral life cycle. However, several mutations in SARS-CoV-2 that may affect the efficacy of United States (US) Food and Drug Administration (FDA)-approved antivirals...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Chlorocebus aethiops

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to Drug Resistance, Viral

Share to HEK293 Cells

Share to Mutation

Share to SARS-CoV-2

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 40772686
DOI: 10.1128/jvi.00821-25
PMCID: PMC12455923

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A luminescent attenuated SARS-CoV-2 for the identification and validation of drug-resistant mutants.PMID 40772686Read ↗

Identification and characterization of a SARS-CoV-2 Mpro G23 deletion ensitrelvir-resistant mutant.Semantic proximity Read ↗

Identification and characterization of a SARS-CoV-2 M <sup>pro</sup> G23 deletion ensitrelvir-resistant mutantSemantic proximity Read ↗

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19Semantic proximity Read ↗

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and ReplicationSemantic proximity Read ↗

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read ↗

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read ↗

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read ↗

Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system.Semantic proximity Read ↗

A cocktail of SARS-CoV-2 S stem helix domain and receptor binding domain human monoclonal antibodies prevents the emergence of viral escape mutants.Semantic proximity Read ↗

Scarless SARS-CoV-2 Genome Engineering and Variant AnalysisSemantic proximity Read ↗

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.Semantic proximity Read ↗

Evolution of Antiviral Drug Resistance in SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.